Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Cancer Biol Ther. 2015;16(12):1830-40. doi: 10.1080/15384047.2015.1078949.

Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.

Author information

1
a Penn State Hershey Cancer Institute; Penn State College of Medicine ; Hershey , PA USA.
2
b University of Virginia Cancer Center; University of Virginia ; Charlottesville , VA USA.
3
c Department of Pharmacology ; Penn State College of Medicine ; Hershey , PA USA.
4
d Center for Applied Proteomics and Molecular Medicine; George Mason University ; Manassas , VA USA.

Abstract

Sphingolipid metabolism has been identified as a potential therapeutic target in cancer. Sphingosine-1-phosphate (S1P) is a potent bioactive sphingolipid metabolite produced by sphingosine kinases-1 and -2 (SPHK1 and SPHK2). Elevated SPHK1 has been found in numerous cancer types and been shown to contribute to survival, chemotherapeutic resistance and malignancy. However, its role in large granular Natural Killer (NK) large granular lymphocyte (LGL) leukemia has not been investigated. Here, we examine SPHK1 as a therapeutic target in LGL leukemia. We found that SPHK1 is overexpressed in peripheral blood mononuclear cells (PBMCs) from LGL leukemia patients which results in elevated S1P in the sera. The use of SPHK1 inhibitors, SKI-II or SKI-178, decreased leukemic NK cell viability and induced caspase-dependent apoptosis. SKI-II and SKI-178 restored the sphingolipid balance by increasing ceramide and decreasing S1P in leukemic NKL cells. SKI-II and SKI-178 also induced apoptosis in primary NK-LGLs from leukemia patients. Mechanistic studies in NK-LGL cell lines demonstrated that SKI-178 and SKI-II induced cell cycle arrest at G2/M. We found that SKI-178 induced phosphorylation of Bcl-2 at Ser70, and that this was dependent on CDK1. We further show that SPHK1 inhibition with SKI-178 leads to decreased JAK-STAT signaling. Our data demonstrate that SPHK1 represents a novel therapeutic target for the treatment of NK-LGL leukemia.

KEYWORDS:

LGL leukemia; SKI-178,SKI-II; apoptosis; large granular lymphocyte; natural killer; sphingosine kinase 1

PMID:
26252351
PMCID:
PMC4847818
DOI:
10.1080/15384047.2015.1078949
[Indexed for MEDLINE]
Free PMC Article

Publication type, MeSH terms, Substances, Grant support

Publication type

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center